Interim statement from the BCSH CLL Guidelines Panel George A Follows1, Adrian Bloor2, Claire Dearden3, Steve Devereux4, Christopher P Fox5, Peter Hillmen6, Ben Kennedy7, Helen McCarthy8, Nilima Parry-Jones9, Piers EM Pa

First Page		Document Content
Date: 2015-07-22 04:38:28 Clinical medicine Medicine Breakthrough therapy Cancer B-cell chronic lymphocytic leukemia Obinutuzumab Ofatumumab Ibrutinib Rituximab Leukemia Idelalisib Phosphoinositide 3-kinase inhibitor		Interim statement from the BCSH CLL Guidelines Panel George A Follows1, Adrian Bloor2, Claire Dearden3, Steve Devereux4, Christopher P Fox5, Peter Hillmen6, Ben Kennedy7, Helen McCarthy8, Nilima Parry-Jones9, Piers EM Pa Add to Reading List Source URL: www.bcshguidelines.com Download Document from Source Website File Size: 553,43 KB Share Document on Facebook

	Interim statement from the BCSH CLL Guidelines Panel George A Follows1, Adrian Bloor2, Claire Dearden3, Steve Devereux4, Christopher P Fox5, Peter Hillmen6, Ben Kennedy7, Helen McCarthy8, Nilima Parry-Jones9, Piers EM Pa DocID: 1qeKO - View Document
	Gazyvaro; INN-obinutuzumab DocID: 15cVk - View Document
	Gazyvaro; INN-obinutuzumab DocID: Ry3S - View Document
	Obinutuzumab (Gazyva®) Injectable Medication Precertification Request Aetna Precertification Notification 503 Sunport Lane, Orlando, FL 32809 DocID: CON6 - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GAZYVA safely and effectively. See full prescribing information for GAZYVA. GAZYVA (obinutuzumab) Injection, for int DocID: oHpm - View Document